EstechPharma Co. Ltd (041910) - Total Liabilities
Based on the latest financial reports, EstechPharma Co. Ltd (041910) has total liabilities worth ₩60.00 Billion KRW (≈ $40.66 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 041910 operating cash flow to assess how effectively this company generates cash.
EstechPharma Co. Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how EstechPharma Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check EstechPharma Co. Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
EstechPharma Co. Ltd Competitors by Total Liabilities
The table below lists competitors of EstechPharma Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Manba Finance Ltd
NSE:MANBA
|
India | Rs14.99 Billion |
|
iLearningEngines, Inc.
NASDAQ:AILE
|
USA | $153.76 Million |
|
Newfield Resources Ltd
AU:NWF
|
Australia | AU$15.64 Million |
|
YES24 Co.Ltd
KQ:053280
|
Korea | ₩312.48 Billion |
|
Vishnu Prakash R Punglia Limited
NSE:VPRPL
|
India | Rs12.39 Billion |
|
Korea Steel Co Ltd
KO:007280
|
Korea | ₩349.24 Billion |
|
Telcoware
KO:078000
|
Korea | ₩24.75 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down EstechPharma Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EstechPharma Co. Ltd (041910) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EstechPharma Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EstechPharma Co. Ltd (2013–2025)
The table below shows the annual total liabilities of EstechPharma Co. Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩60.00 Billion ≈ $40.66 Million |
+922.48% |
| 2024-12-31 | ₩5.87 Billion ≈ $3.98 Million |
-6.35% |
| 2023-12-31 | ₩6.27 Billion ≈ $4.25 Million |
-23.86% |
| 2022-12-31 | ₩8.23 Billion ≈ $5.58 Million |
-25.60% |
| 2021-12-31 | ₩11.06 Billion ≈ $7.50 Million |
-5.90% |
| 2020-12-31 | ₩11.76 Billion ≈ $7.97 Million |
-14.23% |
| 2019-12-31 | ₩13.71 Billion ≈ $9.29 Million |
+50.71% |
| 2018-12-31 | ₩9.09 Billion ≈ $6.16 Million |
-27.66% |
| 2017-12-31 | ₩12.57 Billion ≈ $8.52 Million |
-37.30% |
| 2016-12-31 | ₩20.05 Billion ≈ $13.59 Million |
+4.22% |
| 2015-12-31 | ₩19.24 Billion ≈ $13.04 Million |
-50.12% |
| 2014-12-31 | ₩38.57 Billion ≈ $26.14 Million |
+5.92% |
| 2013-12-31 | ₩36.41 Billion ≈ $24.68 Million |
-- |
About EstechPharma Co. Ltd
EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001. EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.